Data published in the laryngoscope shows ino-3107 resulted in long-term surgery reduction in recurrent respiratory papillomatosis (rrp)

Retrospective trial showed overall response rate (orr) improved to 86% at the end of the second 12-month period (year 2) compared to 72% observed at the end of the initial 12-month phase 1/2 trial (year 1); the complete response (cr) rate improved to 50% for year 2 from 28% for year 1 mean number of surgeries patients needed to control their rrp continued to drop from 4.1 surgeries per year prior to receiving ino-3107 to 1.7 for year 1 to 0.9 for year 2 partial data into the third 12-month period (year 3 - median follow up 2.8 years following initial treatment) continued the trend of improvement and a reduced number of surgeries plymouth meeting, pa. , aug. 11, 2025 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from a retrospective study investigating the long-term clinical and safety response of patients treated with ino-3107 were published online in the laryngoscope under the title "dna immunotherapy (ino-3107) results in long-term surgery reduction in recurrent respiratory papillomatosis (rrp).
INO Ratings Summary
INO Quant Ranking